rp-2

Rp-2'-Deoxyuridine-5'-O-(1-thiotriphosphate) (Rp-dUTP-α-S), a sulfur-containing nucleotide isomer and purinergic P2Y2 receptor agonist, preferentially promotes inositol phosphate accumulation in 1321N1 astrocytoma cells with P2Y2 receptors (EC50 = 12.5 µM) compared to those expressing P2Y4 receptors at a concentration of 10 µM.

PARP-2-IN-3 is used as a potent PARP-2 inhibitor (IC50=0.07 μM) with anti-tumor activity that induces apoptosis and necrosis in cancer cells, and can be used for the study of breast cancer.128-52-56-8

PARP-2-IN-1 is a potent and selective inhibitor of PARP-2 (IC50 of 11.5 nM).

RP-23618 is a non-peptidic antagonist of RANTES.

KRP297 is a PPAR agonist potentially for the treatment of type 2 diabetes and dyslipidemia.

Tyrosinase-related Protein 2 (TRP-2) (181-188) is a peptide derived from TRP-2, specifically corresponding to residues 180-188, and it is the primary epitope within TRP-2 recognized by anti-B16 CTLs. Additionally, it conforms to the binding motif of the MHC class I H2-Kb.

BRP-201 is a selective, novel, and potent inhibitor of mPGES-1 (IC50: 0.42 μM) and is considered a promising therapeutic target for the next generation of anti-inflammatory drugs for the treatment of inflammatory diseases.

PARP-2 1-IN-2, an enantiomer of Veliparib, serves as a potent inhibitor of PARP, demonstrating inhibition constants (Kis) of 2 nM for PARP-2 and 5 nM for PARP-1. This compound exhibits a half-maximal effective concentration (EC50) of 3 nM in cell-based assays evaluating PARP activity [1].

This peptide is a TRP-tyrosinase-related protein. Its immunization results in effective induction of antitumor immunity.

Docetaxel trihydrate (RP-56976 Trihydrate) is an antineoplastic agent that has a unique mechanism of action as an inhibitor of cellular mitosis and that currently plays a central role in the therapy of many solid tumor including breast and lung cancer. Therapy with docetaxel has been associated with a low rate of serum enzyme elevations and rarely to instances of acute hepatic necrosis generally due to severe hypersensitivity reactions or sepsis.

Ketoprofen (RP-19583) is a propionic acid derivative and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. It inhibits cyclo-oxygenase I and II, decreasing the formation of prostaglandin and thromboxane precursors. This reduction in prostaglandin synthesis, mediated by prostaglandin synthase, is responsible for its therapeutic effects. Additionally, Ketoprofen decreases thromboxane A2 formation via thromboxane synthase, inhibiting platelet aggregation.

Docetaxel (RP-56976), a semi-synthetic analog of paclitaxel, is a microtubule depolymerization inhibitor (IC50=0.2 μM) that attenuates the effects of bcl-2 and bcl-xL gene expression and exhibits apoptosis-inducing, anti-tumor activity.

S-(+)-Ketoprofen ((S)-(+)-Ketoprofen) works by blocking the action of a substance in the body called cyclo-oxygenase. It belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). Cyclo-oxygenase is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation and pain. By blocking cyclo-oxygenase, S-(+)-Ketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with Peripheral analgesic action it possesses central analgesic action.S-(+)-Ketoprofen is a non-steroidal anti-inflammatory drug. It is manufactured by Menarini, under the tradename Keral. It is available in the UK, as S-(+)-Ketoprofen trometamol, as a prescription-only drug and in Latin America as Miracox, produced by Stein in Costa Rica. In Italy it is available as an over the counter-drug under the tradename Enantyum. In Lithuania it is available as over the counter-drug uder tradename Dolmen.

Piclamilast (RP 73401) is a PDE4 inhibitor.

Rp-8-CPT-cAMP is a structural combination of the lipophilic and non-hydrolyzable cAMP analogs, 8-CPT-cyclic AMP and Rp-cyclic AMPS .[1] It functions as a site-selective inhibitor of protein kinase A (PKA) type I and II, with preference towards site A of type I and site B of type II.2 By occupying cAMP binding sites at the regulatory subunit of PKA, Rp-8-CPT-cAMP prevents the kinase holoenzyme from dissociative activation.[2],[3]

Intoplicine (RP 60475) dimesylate is a DNA topoisomerase I and II inhibitor belonging to the 7H-benzo[e]pyrido[4,3-b]indole series. It exhibits a strong affinity for DNA (K A = 2 x 10^5 M), resulting in increased linear DNA length.

Secnidazole hemihydrate (RP-14539), an orally ingestible azole derivative antibiotic and imidazole-based Serratia marcescens virulence suppressor, analogously inhibits acylhomoserine lactones, mitigating Pseudomonas aeruginosa pathogenicity through quorum sensing (QS) disruption. This compound exhibits broad-spectrum antimicrobial efficacy against numerous anaerobic Gram-negative and Gram-positive bacteria in vitro. Its therapeutic application spans the study and treatment of ailments including amoebiasis, giardiasis, and bacterial vaginitis [1] [2] [3].

Rp-dGTPαS, an enantiomer of the dNTPαS nucleotide, serves as the substrate for SAMHD1, a critical regulator of cellular dNTP levels that curtails the replication of viruses (HIV-1, etc.) in CD4+ myeloid lineage and resting T cells. The SAMHD1 tetrameric complex facilitates the hydrolysis of Rp-dGQTPαS into 2'-deoxynucleosides and triphosphates [1].